We are offering our innovative "human robust, reproducible & reliable respiratory platform" that is reconstructed from normal and diseased human lung tissue, to dramatically enhance and accelerate respiratory drug discovery.
SCROLL
Presentation at a pandemic preparedness symposium in San Diego, hosted by J&J & BARDA
Yuki Yamamoto, CEO of HiLung, present our activities at Imperial Lung and Airway Organoid Workshop, Imperial College London 29 April 2024.
We have a booth at the Annual Meeting of the Japanese Society of Virology again this year.
Yuki Yamamoto, CEO of HiLung, will present our iPSC-based respiratory MPS (microphysiological system) development innovations, as a panelist at the upcoming 2023 ICCP450/JSSX, to be held in Shizuoka on September 25th through 29th, 2023.
HiLung and UBE Corporation have received Orphan Drug Designation (ODD) from US FDA (Food and Drug Administration) for HL001 – a novel lysophosphatidic acid receptor-1 (LPA1) antagonist under joint development for idiopathic pulmonary fibrosis (IPF).
We have experience in dramatically accelerating the drug discovery process for respiratory diseases based on our extensive experience and recent findings on "lung stem cell biology", including those based on human iPS cell differentiation technology. Our services will assist in efficient preclinical discovery of highly effective therapeutic drug candidates based on well-founded human pathophysiology models we have developed. We will continue to adapt and optimize our human lung model servicing and packaging to better fit our clients' needs, while establishing the additional science and the track record ultimately needed to bring about cell and tissue therapies for respiratory organs.
VIEW MOREOur core technologies and engineering have for the first time enabled a very reliable mass production of human respiratory epithelial cells that essentially replicates human biology. We are applying this core technology to replicate disease pathophysiology for drug discovery purposes and normal physiology for toxicity studies, and will further strengthen it to enable cell therapy and tissue transplantation purposes.
VIEW MOREWe are not currently recruiting.